All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
2 warning events since 2017; the latest 2025-05-07.
From the record
INmune Bio Inc.'s filings since 2017 show 2 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, the latest 2019-06-04); an auditor change (8-K item 4.01, the latest 2025-05-07) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
8 filed years; profitable in 0 of 9.
From the record
INmune Bio Inc.'s 8 filed years say what it did: it rose in 3 of 5 years; the deepest fall was 96% from fiscal 2022 to fiscal 2024; net income was positive in 0 of 9 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 6.6/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: INmune Bio Inc.'s shareholder treatment is put at 6.6 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 34% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -195%: lost 195¢ per shareholder dollar. Leverage 27%: owes 27¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, INmune Bio Inc. lost about 195 cents for every dollar of shareholders' money. Leverage: it owed about 27 cents per dollar of assets, and net share issuance: its share count grew 24.1% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 5% of 102 in its family; net margin -91866%.
From the record
INmune Bio Inc.'s standing among 102 graded names in its industry family: revenue of $50 thousand in fiscal 2025 ranks in the bottom 5% by size; a net margin of -91866% ranks in the bottom 3%; revenue growth of -48.9% a year over the last 3 filed years ranks in the bottom 9% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 36% of 110 in its family for leadership; chief executive since 2025.
From the record
INmune Bio Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Moss, David J (Chief Executive Officer, as filed), filing under that title since 2025-11-18, 12 months (bottom 14% of its family); the 9 officers and directors filing in the last fifteen months have been on the record a median of 7.8 years (top 15%); 10 officer or director changes were reported on Form 8-K since 2023-11-13, against the 9 people in charge now (bottom 8%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 39% of 92 in its family for room to expand.
From the record
INmune Bio Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $25 million against no long-term debt tagged leaves 76.5% of its assets as net cash, top 17% of its family; cash from operations less capital spending is -47248% of revenue (bottom 3%); research spending of 41318% of revenue (top 2%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 25% of 100 in its family for growth drivers.
From the record
INmune Bio Inc.'s growth drivers, from the filed years to fiscal 2025: the newest year grew 257.5% (top 10%); research spending grew 6.6% a year (top 40%) (its annual reports). INmune Bio Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 28% of 72 in its family for expectations against reality.
From the record
INmune Bio Inc.'s newest year against its own record: revenue of $50 thousand in fiscal 2025 came in 1743.9% above the $3 thousand its prior three years' pace pointed to (top 2% of its family); net income of $46 million against a prior three-year average of $33 million (bottom 20%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 3%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made